Drugs / Ginger
Ginger
Trials 18 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 04 trials | ||||||
| Phase 0 | NCT07595640 | Feb 2028 → Jan 2029 expected | blood coagulation disease | University of Valladolid | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT03705832 | Aug 2019 → Feb 2021 | asthma | Emily DiMango, MD | Completed | No outcome recorded |
| Phase 0 | NCT02289235 | May 2019 → Jan 2020 | fatty liver disease, type 2 diabetes mellitus | Shiraz University of Medical Sciences | Completed | No outcome recorded |
| Phase 0 | NCT02670941 | Jan 2016 → Sep 2018 | chemotherapy-induced toxicity | University of Rochester | Terminated | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03617900 | Aug 2018 → May 2019 | puerperal disorder | Thammasat University | Completed | No outcome recorded |
| Phase 26 trials | ||||||
| Phase 2 | NCT02576808 | Oct 2015 → Oct 2017 | allergic rhinitis | Thai Traditional Medical Knowledge Fund | Completed | No outcome recorded |
| Phase 2 | NCT02390648 | Mar 2015 → Feb 2016 | chemotherapy-induced toxicity | Mahidol University | Completed | No outcome recorded |
| Phase 2 | NCT02032251 | Dec 2009 → Sep 2010 | male infertility | Royan Institute | Completed | No outcome recorded |
| Phase 2 | NCT01344538 | Apr 2007 → May 2011 | colorectal cancer | University of Michigan | Completed | No outcome recorded |
| Phase 2 | NCT00065221 | Jun 2003 → Jan 2007 | — | National Center for Complementary and Integrative Health (NCCIH) | Completed | No outcome recorded |
| Phase 2 | NCT00064272 | May 2003 → May 2007 | cancer of unknown primary site | University of Michigan Rogel Cancer Center | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT06787222 | Nov 2024 → Aug 2025 overdue | acne | Hasanuddin University | Active not recruiting | No outcome recorded |
| Phase 2/3 | NCT01733212 | Jun 2010 → Jul 2011 | — | Joel Yarmush | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT06439212 | Jun 2024 → Jan 2025 | tooth disorder | Cairo University | Unknown | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT03755596 | Jan → Apr 2019 | motion sickness | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 4 | NCT00317655 | Apr 2006 → Apr 2007 | — | Ferrosan AS | Completed | No outcome recorded |
| Phase not applicable2 trials | ||||||
| — | NCT06476223 | Jul → Dec 2024 | — | Chulalongkorn University | Unknown | No outcome recorded |
| — | NCT04997889 | Feb → Jun 2024 | — | Chulalongkorn University | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 7 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT06817018 Comparator | Jul 2025 → Feb 2028 expected | neuropathy, painful, sciatica | Leslie Shen | Recruiting | No outcome recorded |
| Phase 2 | NCT04560114 Background | Dec 2020 → Sep 2021 | Athrombia, essential | Centre Francois Baclesse | Completed | No outcome recorded |
| Phase 2 | NCT01429935 Comparator | Jun 2010 → Sep 2011 | impacted teeth, multiple | Qazvin University Of Medical Sciences | Unknown | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07190495 Comparator | Jul 2025 → Aug 2026 overdue | gallbladder disorder | University Tunis El Manar | Recruiting | No outcome recorded |
| Phase 4 | NCT05221892 Comparator | Nov 2021 → Mar 2023 | — | Fundação Educacional Serra dos Órgãos | Completed | No outcome recorded |
| Phase 4 | NCT02809027 Comparator | Jun 2016 → Jun 2017 | — | Chulalongkorn University | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06515652 Comparator | Sep 2023 → Jul 2024 overdue | metabolic syndrome X | Hamdard University | Recruiting | No outcome recorded |
Evidence & citations 17 cited values
Every value below carries the sentence it was read from. 26 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ginger | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07190495 ↗ |
| Known as | Artificial saliva containing cumin and ginger extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06476223 ↗ |
| Known as | Artificial salivary containing cumin and ginger extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04997889 ↗ |
| Known as | dry ginger | “treatment with dry ginger (Z. officinale) extract” NCT03755596 ↗ |
| Known as | dry ginger root | “Oral dose of 160mg dry ginger root (Z. officinale) extract in tablet form.” NCT03755596 ↗ |
| Known as | GIN-106 | “The ginger oil (GIN-106) was steam distilled from fresh ginger grown in Madagascar.” NCT02670941 ↗ |
| Known as | Ginger extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02576808 ↗ |
| Known as | Ginger powder | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06439212 ↗ |
| Known as | Ginger Root Extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01344538 ↗ |
| Known as | Z. officinale | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06787222 ↗ |
| Known as | Z. officinale extract | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03755596 ↗ |
| Known as | Zingiber officinale | “The goal of this clinical trial is to investigate the effectivity and safety of mild to moderate acne vulgaris therapy using Zingiber officinale 5 % transdermal patch.” NCT06787222 ↗1“Inhalation will be carried out via an inhaler stick containing essential oils (Mentha x Piperita; Citrus Limon; Zingiber Officinale)” NCT04560114 ↗ |
| Known as | Zingiber officinale Roscoe | “Ginger (Zingiber officinale Roscoe) has been cultivated for medicinal and culinary purposes for at least two millennia.” NCT02289235 ↗ |
| Known as | Zingiber officinalis | “Ginger (Zingiber officinalis) is already used in traditional folk medicine to treat nausea and vomiting in various populations.” NCT00065221 ↗ |
| Action | Inhibit | “Ginger has been shown to inhibit COX” PMID 24760534 ↗ Apr 2014 |
| Modality | Traditional medicine (herbal / TCM) | “Ginger (Zingiber officinalis) is already used in traditional folk medicine to treat nausea and vomiting in various populations.” NCT00065221 ↗ |
| Route | Oral | “Given orally” NCT00064272 ↗ |